Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone.
Ten fasting subjects received 200 mg cimetidine orally either with water or 11 g aluminium phosphate mixture in a randomized, single dose, two-way cross-over study. Blood samples were taken for 12 h and urine was collected for 24 h. Cimetidine in plasma and urine was analysed by HPLC. There were no significant differences between the treatments with respect to peak plasma concentration, time to peak plasma concentration, area under the plasma concentration-time curve, and urinary excretion. In 12 healthy subjects the absorption of prednisolone was investigated when given alone and together with 11 g aluminium phosphate. Blood samples were taken over 16 h and prednisolone in plasma was analysed by HPLC. There were no significant differences in the values of area under curve (AUC), Cmax and tmax. The results indicate that aluminium phosphate does not reduce the bioavailability of cimetidine and prednisolone.
D000328:Adult; D017607:Aluminum Compounds; D000863:Antacids / Q000494:pharmacology*; D001682:Biological Availability; D002927:Cimetidine / Q000378:metabolism*; D004347:Drug Interactions; D006801:Humans; D007700:Kinetics; D008297:Male; D010710:Phosphates / Q000494:pharmacology*; D011239:Prednisolone / Q000378:metabolism*
D017607:Aluminum Compounds; D000863:Antacids; D010710:Phosphates; D002927:Cimetidine; D011239:Prednisolone; C012714:aluminum phosphate